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INTRODUCTION
Drug-induced hypersensitivity syndrome is a severe adverse
drug reaction, which often manifests as an erythematous skin
eruption, fever, lymphadenopathy, peripheral blood eosino-
philia, and visceral organ involvement (1). Many drugs cause
hypersensitivity syndrome, including anticonvulsants, sul-
fonamides, dapsone, allopurinol, minocycline, and gold salts
(2). Mexiletine is an antiarrhythmic agent that has been used
to treat ventricular tachycardia for more than 30 yr (3). Since
the first report by Higa et al. (4). in 1997, a few cases of mex-
iletine-induced hypersensitivity syndrome have been report-
ed, especially in Japanese males over 45 yr of age (5-8). These
cases manifested with fever, rash, peripheral blood eosino-
philia, elevation of liver transaminase enzymes without other
organ involvement. Here, we present the first case of mexile-
tine-induced hypersensitivity syndrome with lung involve-
ment, which is also the first case of mexiletine-induced hy-
persensitivity syndrome in Korea. This case manifested as
eosinophilic pneumonia, in addition to fever, a papuloery-
thematous skin rash, peripheral blood eosinophilia, and liver
dysfunction.
CASE REPORT
An 82-yr-old man was admitted to the hospital with a fever
and cough. The patient had been diagnosed with an arrhyth-
mia associated with dilated cardiomyopathy 9 months earlier
and had been taking mexiletine for 5 months in addition to
furosemide and spironolactone, which was continued since the
diagnosis. He developed a fever, cough, and sputum 1 week
before admission (Fig. 1). He was a retired pharmacist who
lived in downtown Seoul, Korea. On physical examination,
variable-sized, fused erythematous macules and plaques cov-
ered his entire body, including the trunk and extremities; this
rash developed on the day of admission (Fig. 2). His body
temperature was 38.3℃, and his respiratory rate was 22 times
per min. Auscultation of the lungs disclosed diminished breath
sounds throughout both lungs, with crackles at the bases.
Laboratory studies showed leukocytosis (13,700/μ L) with eo-
sinophilia (3,310/μ L; 24.2% of the white blood cells) in the
peripheral blood. Liver dysfunction was also detected (aspar-
tate transaminase 193 U/L; alanine transaminase 321 U/L,
lactate dehydrogenase 290 U/L). Chest radiographs showed
multiple increased opacities with a patchy distribution in both
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A Case of Mexiletine-induced Hypersensitivity Syndrome Presenting
as Eosinophilic Pneumonia
An 82-yr-old man was presented with fever and cough accompanied by generalized
erythematous rash. He had taken mexiletine for 5 months, as he had been diag-
nosed with dilated cardiomyopathy and ventricular arrhythmia. Laboratory studies
showed peripheral blood eosinophilia and elevated liver transaminase levels. Chest
radiographs showed multiple nodular consolidations in both lungs. Biopsies of the
lung and skin lesions revealed eosinophilic infiltration. After a thorough review of
his medication history, mexiletine was suspected as the etiologic agent. After dis-
continuing the mexiletine and starting oral prednisolone, the patient improved, and
the skin and lung lesions disappeared. Subsequently, mexiletine was confirmed as
the causative agent based on a positive patch test. Drug-induced hypersensitivity
syndrome is a severe adverse reaction to drugs and results from treatment with
anticonvulsants, allopurinol, sulfonamides, and many other drugs. Several cases
of mexiletine-induced hypersensitivity syndrome have been reported in older Japanese
males with manifestation of fever, rash, peripheral blood eosinophilia, liver dysfunc-
tion without other organ involvement. Here, we report a case of mexiletine-induced
hypersensitivity syndrome which presented as eosinophilic pneumonia in a Korean
male.
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lungs (Fig. 3A). Chest computed tomography (CT) on admis-
sion showed multiple nodular consolidations with ground-
glass density in both hemithoraxes and multiple mediastinal
lymphadenopathy (Fig. 3B). A fine needle aspiration biopsy
of a lung lesion was performed and showed eosinophilic infil-
tration with histiocytes, and granular pneumocytes with an
organizing alveolar exudate (Fig. 4A). In addition, a right
abdominal skin lesion was biopsied. The dermis showed ex-
travasated red blood cells and moderate perivascular infiltra-
tion of lymphocytes and eosinophils (Fig. 4B). After admis-
sion, he was diagnosed with type II diabetes mellitus for the
first time based on a fasting serum glucose of 183 mg/dL and
hemoglobin A1c of 8.6%. The patient was diagnosed with
drug-induced hypersensitivity syndrome based on the clini-
cal findings and laboratory evidence. The mexiletine was sus-
pected to cause theses adverse reactions and was withdrawn,
while furosemide and spironolactone was continued. For the
treatment of severe immune response, prednisolone 0.5 mg/
kg was given for 10 days and tapered. Subsequently, his tem-
perature decreased, with resolution of the blood eosinophil-
ia, liver dysfunction, and cutaneous and lung lesions (Fig. 3C).
With the resolution of adverse reactions, digoxin was susb-
stituted for mexiletine to treat arrhythmia. 
Four months after resolution of the adverse findings, a patch
test was performed to confirm the etiologic diagnosis. Mexile-
tine (Mexitil
�, Boehringer Ingelheim Korea, Seoul, Korea),
furosemide (Lasix
�, Handok Pharmaceuticals Co., Seoul, Korea),
and spironolactone (Aldactone
�, Pharmacia Ltd., UK) at con-
centrations of 0, 1, 2, 5, 10, and 20% in petrolatum was ap-
plied at the back of the patient using Finn chambers on Scan-
por tape for 48 hr. At 30 min and 48 hr after removal of the
tape, the responses were scored according to the Internation-
al Contact Dermatitis Research Group guidelines (9). Weak-
ly positive reactions were detected with 5, 10, and 20% mex-
iletine, while ten control subjects showed negative result to
the test. Based on clinical course and patch test, we were able
to identify mexiletine as the etiologic agent for the develop-
ment of drug-induced hypersensitivity syndrome. To explore
the association of these events with human herpes virus 6
(HHV-6) infections, we performed polymerase chain reaction
(PCR) analysis for HHV-6 in the serum of the patient taken
at the time of patch test. The PCR analysis did not detect
HHV-6 DNA. 
DISCUSSION
Drug-induced hypersensitivity syndrome is the name for
the severe adverse reactions to drugs as a result of systemic
immune responses and is often called DRESS (drug reaction
Fig. 1. Clinical courses and med-
ications. These graphs illustrate
clinical course including fever,
rash, lung lesions, peripheral
blood eosinophil count (solid
line) and serum alanine transam-
inase (ALT, dashed line) over
time. Under the X-axis, the medi-
cations used for the treatment
of heart failure and systemic
steroids are shown. 
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Fig. 2. Skin lesions on admission. There were variable-sized, occa-
sionally fused, erythematous macules and plaques covering the
skin of the entire body.150 S.-P. Lee, S.-H. Kim, T.H. Kim, et al.
with eosinophilia and systemic symptoms) (10). Anticonvul-
sants such as carbamazepine and phenytoin are the most com-
mon etiologic agents causing drug-induced hypersensitivity
syndrome (11). In addition, allopurinol, sulfonamides, dap-
sone, and minocycline can cause these reactions. Mexiletine
has been reported to cause severe hypersensitivity reactions,
including drug-induced hypersensitivity syndrome (or DR-
ESS). Although mexiletine is prescribed worldwide, all pre-
Fig. 3. Imaging examination of the chest. (A) Simple radiographs of the chest on admission show diffuse heterogeneous increased opaci-
ties with a patchy distribution in both lungs. (B) Chest CT on admission shows multiple nodular consolidations with ground-glass density
in both hemithoraxes and multiple mediastinal lymphadenopathy. (C) Simple radiographs of the chest after discontinuing the mexiletine
and then treating the patient with oral prednisolone. The multiple infiltrative lesions disappeared from both lungs.
A B C
Fig. 4. Microscopic observation of the biopsy specimen. (A) The tissue of the lung lesion shows eosinophilic infiltration with histiocytes and
granular pneumocytes (H&E stain, ×400). (B) The epidermis shows parakeratosis, exocytosis of lymphocytes with spongiosis, and vac-
uolization. The dermis shows extravasated red blood cells and moderate perivascular lymphocytes and eosinophils (H&E stain, ×400).
A B
Onset time
after 
medication
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Refe-
rences
Age
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Peripheral
blood 
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Lym-
phade
nopathy
Liver 
dys-
function
Patch
test
Lung
involve-
ment
Fever Skin manifestations
4 1997 Japanese Male 64 30 days Morbilliform  + + + +
5 2001 Japanese Male 55 1 month Erythema with pustules + + + +
6 2004 Japanese Male 46 41 days Maculopapular + + + +
7 2005 Japanese Male 66 26 days Erythema and papule + + +
8 2006 Japanese Male 45 6 months Papuloerythematous + + + + +
This 2010 Korean Male 85 5  months Papuloerythematous + + + + + +
case
Table 1. Clinical characteristics of reported cases of mexiletine-induced hypersensitivity syndromeHypersensitivity Syndrome by Mexiletine 151
viously reported cases of mexiletine-induced hypersensitivity
syndrome have been Japanese, suggesting a genetic predispo-
sition (Table 1). The present case is the first report in a non-
Japanese population. Despite ethnic differences, the Korean
and Japanese populations share much the same genetic back-
ground, and the exclusive incidence of mexiletine-induced
hypersensitivity syndrome in Far Eastern countries implies
that genetic susceptibility underlies its pathogenesis. While
genetic variants associated with the development of drug in-
duced hypersensitivity syndrome are not well defined, the
human leukocyte antigen HLA-B*1502 is reported to be sig-
nificantly associated with the development of carbamazepine-
induced Stevens-Johnson syndrome (SJS) and toxic epidermal
necorlysis (TEN) (12). This genetic association may be eth-
nicity specific, in that strong association is observed in Han-
Chinese, not in Caucasians (13). These finding can explain
relatively higher incidence of the event in Han-Chinese than
in Caucasians (12, 14). Like carbamazepine-induced SJS and
TEN, high incidence of mexiletine-induced hypersensitivi-
ty syndrome in Far Eastern countries maybe due to ethnici-
ty specific genetic predisposition. In addition to ethnic char-
acteristics, all reported cases have developed in relatively old
males, which suggests a sex and age predilection.
Internal organ involvement is a specific finding of hyper-
sensitivity syndrome, and the specific organ involvement often
depends on the etiologic drug (1). Allopurinol-induced reac-
tions frequently involve the kidney, whereas phenytoin and
dapsone often cause liver dysfunction. The previous reports of
mexiletine-induced hypersensitivity syndrome did not reveal
the specific organ involvement, except for liver dysfunction
(Table 1). Ours is the first report of lung involvement in mex-
iletine-induced hypersensitivity syndrome. In this report, we
proved eosinophilic lung infiltration with not only imaging
studies but also microscopic examination of the lung lesions.
In many cases of drug-induced hypersensitivity syndrome, a
clinical response develops 3 weeks to 3 months after starting
a medication. This was also true for mexiletine-induced cases
(Table 1), except for that reported by Yagami et al. (8) and
the present case. In these latter two cases, the patients devel-
oped clinical manifestations after 5 or 6 months of medication,
and patch tests proved mexiletine was the causative agent.
The mechanism for the immunogenicity of these drugs is
not clear, although a role of reactive drug metabolites in ini-
tiating an immune response via hapten formation has been
suggested (15). Recently, the involvement of viral infection in
the pathogenesis of drug-induced hypersensitivity syndrome
has been explored intensively. Although we did not confirm
the viral association in this case, some previous case studies
of mexiletine-induced hypersensitivity syndrome have sug-
gested a relationship between human herpes virus 6 and the
development of systemic immune responses (6-8).
In conclusion, we report the first case of mexiletine-induced
hypersensitivity syndrome with lung eosinophilic infiltrates.
This is also the first report of these reactions in a non-Japanese
population.
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